RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

RT @ElizSMcKenna: Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework…

Going to #AACR23 Methods Workshops on Clinical Trial Design? In @CD_AACR - @lillian_siu & colleagues provide a framework for next-gen clinical trials to transform scientific discoveries to clinical utility: The Future of Clinical Trial Design in #Oncol

RT @ElizSMcKenna: The #AACR22 Opening Plenary Session is on Decoding Cancer Complexity, Integrating Science, Transforming Patient Outcomes…

The #AACR22 Opening Plenary Session is on Decoding Cancer Complexity, Integrating Science, Transforming Patient Outcomes - ICYMI in @CD_AACR: The Future of #ClinicalTrials Design in #oncology by @lillian_siu and colleagues @pmcancercentre @UofT https://t.

RT @CD_AACR: #ICYMI: From the special anniversary issue, The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico and Aaron Han…

RT @CD_AACR: #ICYMI: From the special anniversary issue, The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico and Aaron Han…

#ICYMI: From the special anniversary issue, The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico and Aaron Hansen. https://t.co/6BeixOUbIa @albirunirazak, @Philippe_Bedard, @lillian_siu @pmcancercentre @UofT #CDturns10 https://t.co/uXyPfWv

RT @mtmdphd: The Future of Clinical Trial Design in Oncology [Apr 2, 2021] Spreafico et al. @lillian_siu @CD_AACR https://t.co/ZR6zHXycak…

RT @mtmdphd: The Future of Clinical Trial Design in Oncology [Apr 2, 2021] Spreafico et al. @lillian_siu @CD_AACR https://t.co/ZR6zHXycak…

The Future of Clinical Trial Design in Oncology [Apr 2, 2021] Spreafico et al. @lillian_siu @CD_AACR https://t.co/ZR6zHXycak #ClinicalTrials #ctsm

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @mtmdphd: The Future of Clinical Trial Design in Oncology [Apr 2, 2021] Spreafico et al. @lillian_siu @CD_AACR https://t.co/ZR6zHXgALK #…

The Future of Clinical Trial Design in Oncology [Apr 2, 2021] Spreafico et al. @lillian_siu @CD_AACR https://t.co/ZR6zHXgALK #ClinicalTrials #ctsm https://t.co/OMraT4aOvw

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

It is a pinch of flavor (and to seek approval in any case). However, the control arm is not changed (I.e. dexa arm in whole myeloma trials)

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

“The future of clinical trial design in oncology” (colorized) https://t.co/Ygh7bWtcWj https://t.co/YGpCpHlR0c

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

RT @DavidSteensma: As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten…

As a student, the paradigm of Phase I, II & randomized III trials in oncology made sense. Since then, things have gotten more complicated: Phase 1b/2a/2b, "Phase 0", expansion & enrichment cohorts, safety run-ins, adaptive design, baskets/umbrellas

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @TaliLev123: Watching the Session: Clinical Trial Design: Innovations and Controversies dedicated to Jose Baselga at #AACR21? ICYMI in @…

RT @MLPOncoData: The Future of Clinical Trial Design in Oncology https://t.co/hgoPiTb4I6 https://t.co/RiVvCrafyl

RT @MLPOncoData: The Future of Clinical Trial Design in Oncology https://t.co/hgoPiTb4I6 https://t.co/RiVvCrafyl

RT @MLPOncoData: The Future of Clinical Trial Design in Oncology https://t.co/hgoPiTb4I6 https://t.co/RiVvCrafyl

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @MLPOncoData: The Future of Clinical Trial Design in Oncology https://t.co/hgoPiTb4I6 https://t.co/RiVvCrafyl

The Future of Clinical Trial Design in Oncology https://t.co/hgoPiTb4I6 https://t.co/RiVvCrafyl

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @VivekSubbiah: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/61U7SlmKnN

RT @TaliLev123: Watching the Session: Clinical Trial Design: Innovations and Controversies dedicated to Jose Baselga at #AACR21? ICYMI in @…

RT @TaliLev123: Watching the Session: Clinical Trial Design: Innovations and Controversies dedicated to Jose Baselga at #AACR21? ICYMI in @…

Watching the Session: Clinical Trial Design: Innovations and Controversies dedicated to Jose Baselga at #AACR21? ICYMI in @CD_AACR Review: The Future of #ClinicalTrials Design in #oncology, by @lillian_siu https://t.co/wg2gtLUlOw

RT @TaliLev123: Watching the Methods Workshop: Clinical Trial Design: Part 1 at #AACR21? ICYMI in @CD_AACR: Review: The Future of #Clinical…

Watching the Methods Workshop: Clinical Trial Design: Part 1 at #AACR21? ICYMI in @CD_AACR: Review: The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico, Aaron Hansen, @albirunirazak @Philippe_Bedard @lillian_siu @pmcancercentre @UofT https

RT @aftimosp: Do not miss this review in @CD_AACR if you are interested in new drug development in oncology. It comprehensively reviews the…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: Do not miss this review in @CD_AACR if you are interested in new drug development in oncology. It comprehensively reviews the…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: Do not miss this review in @CD_AACR if you are interested in new drug development in oncology. It comprehensively reviews the…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: #OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized kn…

RT @aftimosp: Do not miss this review in @CD_AACR if you are interested in new drug development in oncology. It comprehensively reviews the…

Do not miss this review in @CD_AACR if you are interested in new drug development in oncology. It comprehensively reviews the state of clinical research, the developments in methodology, and the next steps forward

#OncoAlert "Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized knowledge and collective learning, through the joint efforts of all key stakeholders including investigators and patients" https://t.

https://t.co/fm5wWfnNeb https://t.co/QkaoKXBmQ7

RT @CD_AACR: In the 10th Anniversary Special Issue: The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico, Aaron Hansen, @al…

RT @CD_AACR: In the 10th Anniversary Special Issue: The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico, Aaron Hansen, @al…

RT @CD_AACR: In the 10th Anniversary Special Issue: The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico, Aaron Hansen, @al…

In the 10th Anniversary Special Issue: The Future of #ClinicalTrials Design in #oncology, by Anna Spreafico, Aaron Hansen, @albirunirazak, @Philippe_Bedard, and @lillian_siu. @pmcancercentre @UofT #CDturns10 https://t.co/wBZZXWoT6Q https://t.co/KZMLendep

RT @nanudasmd: A well written piece on future clinical trial design to improve the efficiency and speed of oncologic drug development @CD_A…

RT @nanudasmd: A well written piece on future clinical trial design to improve the efficiency and speed of oncologic drug development @CD_A…

RT @nanudasmd: A well written piece on future clinical trial design to improve the efficiency and speed of oncologic drug development @CD_A…

RT @nanudasmd: A well written piece on future clinical trial design to improve the efficiency and speed of oncologic drug development @CD_A…

RT @nanudasmd: A well written piece on future clinical trial design to improve the efficiency and speed of oncologic drug development @CD_A…

A well written piece on future clinical trial design to improve the efficiency and speed of oncologic drug development @CD_AACR https://t.co/HtctyZ8NoJ

The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/qcmBhstrF6

RT @MarceloCorassa: This last edition of @CD_AACR journal brings some amazing reviews! This one particularly is a piece from the @pmcancerc…

RT @weldeiry: The Future of Clinical Trial Design in Oncology https://t.co/bQ7MCrp8xB

RT @weldeiry: The Future of Clinical Trial Design in Oncology https://t.co/bQ7MCrp8xB

RT @Cartercao2: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/GrgAdUErPI

The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/GrgAdUErPI

RT @MarceloCorassa: This last edition of @CD_AACR journal brings some amazing reviews! This one particularly is a piece from the @pmcancerc…

RT @weldeiry: The Future of Clinical Trial Design in Oncology https://t.co/bQ7MCrp8xB

RT @LuciaRaimondoMD: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/sEgAiKeZwU

RT @weldeiry: The Future of Clinical Trial Design in Oncology https://t.co/bQ7MCrp8xB

RT @MarceloCorassa: This last edition of @CD_AACR journal brings some amazing reviews! This one particularly is a piece from the @pmcancerc…

RT @weldeiry: The Future of Clinical Trial Design in Oncology https://t.co/bQ7MCrp8xB

The Future of Clinical Trial Design in Oncology https://t.co/bQ7MCrp8xB

RT @MarceloCorassa: This last edition of @CD_AACR journal brings some amazing reviews! This one particularly is a piece from the @pmcancerc…

This last edition of @CD_AACR journal brings some amazing reviews! This one particularly is a piece from the @pmcancercentre Phase 1 crew that everyone who works in the oncology world should read. @lillian_siu @Philippe_Bedard https://t.co/LaAzkU20OG

RT @LuciaRaimondoMD: The Future of Clinical Trial Design in Oncology | Cancer Discovery https://t.co/sEgAiKeZwU